Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
argenx to Present at Upcoming Investor Conferences
01:00am, Friday, 03'rd Sep 2021
September 3, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and canc
argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis
01:00am, Wednesday, 25'th Aug 2021
Breda, the Netherlands – August 2 5 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and
argenx: R&D Day Goes Unnoticed
11:22am, Monday, 23'rd Aug 2021
argenx: R&D Day Goes Unnoticed
argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference
01:00am, Wednesday, 04'th Aug 2021
August 4, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer,
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2021 Results - Earnings Call Transcript
04:31am, Sunday, 01'st Aug 2021
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2021 Results - Earnings Call Transcript
Recap: argenx Q2 Earnings
07:24am, Thursday, 29'th Jul 2021
Shares of argenx (NASDAQ:ARGX) decreased 4.8% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 162.86% over the past year to $1.98, which may not
argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update
01:00am, Thursday, 29'th Jul 2021
- Completion of enrollment expected by year-end for ADAPT-SC and ADVANCE (IV) trials of efgartigimod; topline data for both trials expected in first half of 2022
argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021
01:00am, Thursday, 22'nd Jul 2021
July 22, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer,
argenx to Host Virtual R&D Day on July 20, 2021
01:00am, Wednesday, 14'th Jul 2021
July 14, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer,
argenx: Next Phase Of Growth With Efgartigimod And ARGX-117
12:36pm, Wednesday, 30'th Jun 2021
One of argenx's main competitors, Immunovant, suffered clinical setbacks this year and these setbacks have further solidified efgartigimod's potential best-in-class position. argenx to become a commer
Results from ADAPT showed treatment with efgartigimod provided clinically meaningful improvement s in strength and quality of life measures in g eneralized m yasthenia g ravis (gMG )
Argenx Is a Biotech Stock With Big Potential
08:17am, Tuesday, 15'th Jun 2021
The company's main selling point is a drug called efgartigimod, which the company is testing in six different diseases.
argenx (ARGX) to Regain AML Candidate After J&J's Dismissal
12:02pm, Tuesday, 08'th Jun 2021
argenx (ARGX) is developing cusatuzumab as potential treatment for acute myeloid leukemia. However, its partner, J&J, decided to discontinue the development agreement with the company for the candidat
Argenx Regains Global Rights from Johnson & Johnson to Blood Cancer Candidate Cusatuzumab
08:31am, Monday, 07'th Jun 2021
Johnson & Johnson (NYSE: JNJ) has walked away from a $1.6 billion blood cancer candidate deal with Argenx SE (NASDAQ: ARGX) for the CD70-targeting cusatuzumab. The pair first came together to dev
argenx to regain global rights to cusatuzumab
01:00am, Monday, 07'th Jun 2021
Regulated Information/Inside Information
